MD Biosciences, an international provider of inflammatory research products and pre-clinical services, has entered into an agreement with BD (Becton Dickinson and Company) Lee Laboratories to sell PG-PS (peptidoglycan-polysaccharide polymer streptococcus cell wall extract) products. BD Lee Laboratories approached MD Biosciences for its established leadership in inflammations research and the agreement will serve to expand and strengthen MD Biosciences inflammatory research product line, MD Biosciences announced here.

PG-PS is purified polymers produced from the cell walls of Streptococcus pyogenes Group A. The use of these polymers in in vivo models of disease induces an acute and chronic inflammatory reaction, which can evolve into a remittent, arthritic response that is representative of naturally caused inflammatory disorders. "The addition of PG-PS will complement our focused product line of inflammatory research reagents and will provide an additional resource for clients who are engaged in in vivo models of disease for their drug discovery efforts," commented Amy Clausen, marketing manager for MD Biosciences.

PG-PS is a valuable resource to researchers involved in inflammatory drug discovery. The induction of a biphasic inflammatory response in disease models is used for the evaluations and studies of anti-inflammatory drugs and therapies for inflammatory diseases such as arthritis, granulomatous enterocolitis (resembling Crohn's disease), and others.

Lee Laboratories, a fully owned subsidiary of BD (Becton Dickinson), offers reagents and services for diagnostics and inflammation research. BD is a medical technology company that serves life science researchers, clinical laboratories, and the healthcare industry.